A Trial of Novaferon in Asymptomatic or Mild COVID-19 Patients

Beijing 302 Hospital300 enrolled

Overview

This is a phase III randomized, double blinded, placebo-controlled multi-center study to assess the efficacy and safety of aerosolized Novaferon for the treatment of asymptomatic or mildly patients infected with SARS-CoV-2.

Since the outbreak of New Coronavirus pneumonia (COVID-19) in late 2019, epidemics around the world are still developing. There are about 200 million confirmed cases in the world, including about 4.26 million deaths until August 5, 2021, which has become a major disaster for human being. Most of SARS-CoV-2 infection are asymptomatic or mild cases, which is the main factor causing viral transmission. Although COVID-19 patients have immune protection after cured or vaccinated, there still be a percentage of people vaccinated who still get sick, hospitalized, or die caused by COVID-19. COVID-19 vaccine breakthrough and reinfection cases became one of key problems for COVID-19 prevention and control. In addition, SARS-CoV-2 variants circulated in the world. However, some variants were associated with disease severity, the performance of vaccines, therapeutic medicines, diagnostic tools, or other public health and social measures. Variants (e.g., Delta variant) caused some vaccine breakthrough cases. There is an urgent need for effective antiviral drugs. Novaferon is a marketed antiviral drug in China and proved to have more than ten-fold antiviral potency than that of similar interferon α-2b. Novaferon exerts antiviral activity by three ways: blocking virus entry into cells, inducing expression of antiviral genes and proteins (e.g., MX1 and OAS), and promoting apoptosis of infected cells. In vitro experimental study showed Novaferon exhibited anti-SARS-CoV-2 effects at the cellular level. A randomized, open-label, parallel-group trial demonstrated that aerosolized Novaferon expedited clearance and negative conversion of SARS-CoV-2, which provide the rational for large-scale clinical studies to verify the efficacy of Novaferon as a potential antiviral drug for COVID-19. Inhalation administration has advantages over systemic administration in reducing adverse drug reactions, promoting the distribution of drugs in respiratory tract, and thus enhancing the mucosal immunity. This is a phase III randomized, double blinded, placebo-controlled multi-center study to assess the efficacy, and safety of aerosolized Novaferon for the treatment of asymptomatic patients or patients with mild COVID-19.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

300

Conditions

SARS-CoV2 Infection

Interventions

Recombinant cytokine gene derived protein injectionDRUG

Aerosolized Novaferon, given 20 ug BID, daily for 7 days, plus Standard of Care. Inhaled Saline (placebo), given BID, daily for 7 days, plus Standard of Care.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria:1.Patient capable of giving consent, or, when the patient is not capable of giving consent, by his or her legal/authorized representatives prior to initiation of any study procedures. 2.Male or female, between 18 and 65 years of age at the time of consent. 3.Laboratory-confirmed SARS-CoV-2 infection as determined by RT-PCR in nasopharyngeal or oropharyngeal swabs \< 72 hours prior to enrollment. 4Patients with asymptomatics or mild COVID-19, including: 1. Patients with asymptomatic infections refer to those with positive testing results in etiological detection of SARS-CoV-2 in swabs, but without any relevant clinical manifestations, such as self-perceived or clinically identified symptoms or signs, including fever, cough and sore throat, and without any typical imaging features of COVID-19 in their CT scans. 2. Patients with mild SARS-COV-2 infections refer to those who are infected with SARS-COV-2 presenting mild symptoms in accordance with Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Revision 8): mild clinical symptoms, and no findings of pneumonia in chest CT images. \- Exclusion Criteria:1.Patients classified into Moderate, Severe, and Critical cases according to the Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial 8th Edition) 2.Females who are breast-feeding, lactating, pregnant or intending to become pregnant 3.Patients who are receiving any treatment with interferon or participating in other clinical studies of antiviral therapy. 4.Patients who are unable to collaborate due to poor mental health, suffering from psychiatric illness, or incapable of controlling themselves or expressing clearly. 5.Patients excluded in the opinion of the investigators. \-

Outcomes

Primary Outcomes

Time of negative detection of SARS-CoV-2 RNA

Nucleic acid detection twice at a 24-hour interval

Time frame: Day 1 to Day 28

Secondary Outcomes

Rate of clinical progression

at least 4 points on 8-point ordinal Scale developed by WHO

Time frame: Day 1 to Day 28

the change of viral load

viral load cannot be detected

Time frame: Day 1 to Day 28

detection rate of SARS-CoV-2 RNA

cannot detect SARS-CoV-2 RNA

Time frame: Day 1 to Day 28

Rate of clinical progression in patients vaccinated

Time of negative detection of SARS-CoV-2 RNA in patients vaccinated

Time frame: Day 1 to Day 28

Rate of clinical progression in subgroup of patients vaccinated

at least 4 points on 8-point ordinal Scale developed by WHO

Time frame: Day 1 to Day 28

Rate of clinical progression in patients infected with variants( Delta strain, et al)

at least 4 points on 8-point ordinal Scale developed by WHO

Time frame: Day 1 to Day 28

Safety and tolerability

AE score

Time frame: Day 1 to Day 28

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.